title: Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
abstract: The aim of this study was to evaluate the effect of gemigliptin vs sitagliptin or glimepiride as initial combination therapy with metformin on glycaemic variability and to assess the correlation between glycaemic variability reduction and the dipeptidyl peptidase-4 (DPP-4) inhibition in patients with type 2 diabetes. This multicentre, randomized, active-controlled, open-label exploratory study included 69 patients with HbA1c > 7.5%. Subjects were randomized to receive gemigliptin 50 mg (n = 24), sitagliptin 100 mg (n = 23) or glimepiride 2 mg (n = 22) for 12 weeks. After 12 weeks, the change in mean amplitude of glycaemic excursion (MAGE) compared with baseline was significantly lower in the DPP-4 inhibitor groups compared with that in patients who received glimepiride. Furthermore, the standard deviation (SD) of glucose was significantly lower in patients who received gemigliptin than that in patients who received sitagliptin or glimepiride. The DPP-4 inhibition was significantly correlated with changes in MAGE and SD of glucose. In conclusion, gemigliptin and sitagliptin were more effective than glimepiride in reducing glycaemic variability as initial combination therapy with metformin in patients with type 2 diabetes, and the DPP-4 inhibition was associated with a reduction in glycaemic variability.
authors.affiliation: Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
authors.forename: Se E
authors.initials: SE
authors.lastname: Park
authors.affiliation: Department of Internal Medicine, Severance Hospital, University of Yonsei University College of Medicine, Seoul, Republic of Korea.
authors.forename: Byung W
authors.initials: BW
authors.lastname: Lee
authors.affiliation: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
authors.forename: Jae H
authors.initials: JH
authors.lastname: Kim
authors.affiliation: Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
authors.forename: Woo J
authors.initials: WJ
authors.lastname: Lee
authors.affiliation: Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea School of Medicine, Seoul, Republic of Korea.
authors.forename: Jae H
authors.initials: JH
authors.lastname: Cho
authors.affiliation: Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
authors.forename: Chang H
authors.initials: CH
authors.lastname: Jung
authors.affiliation: Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea School of Medicine, Seoul, Republic of Korea.
authors.forename: Seung H
authors.initials: SH
authors.lastname: Lee
authors.affiliation: Department of Internal Medicine, Dong-A University Medical Center, Busan, Republic of Korea.
authors.forename: Sunghwan
authors.initials: S
authors.lastname: Suh
authors.affiliation: LG Life Sciences, Seoul, Republic of Korea.
authors.forename: Gwong C
authors.initials: GC
authors.lastname: Hur
authors.affiliation: LG Life Sciences, Seoul, Republic of Korea.
authors.forename: Sung H
authors.initials: SH
authors.lastname: Kim
authors.affiliation: LG Life Sciences, Seoul, Republic of Korea.
authors.forename: Young H
authors.initials: YH
authors.lastname: Jang
authors.affiliation: Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
authors.forename: Cheol Y
authors.identifier: 0000-0002-9415-9965
authors.initials: CY
authors.lastname: Park
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008297:Male; D008687:Metformin / Q000008:administration & dosage*; D008875:Middle Aged; D010881:Piperidones / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D000068900:Sitagliptin Phosphate / Q000008:administration & dosage; D013453:Sulfonylurea Compounds / Q000008:administration & dosage; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin; D010881:Piperidones; D011743:Pyrimidines; D000068900:Sitagliptin Phosphate; D013453:Sulfonylurea Compounds; C534891:LC15-0444; C517652:hemoglobin A1c protein, human; C057619:glimepiride
keywords: dipeptidyl peptidase-4 inhibition; gemigliptin; glycaemic variability; type 2 diabetes